Silverarc Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Silverarc Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.1M	Sell	71,552 -10,913	-13%	-$3.38M	2.35%	15
2025 Q4	$24.3M	Buy	82,465 +31,255	+61%	+$5.82M	3.38%	9
2025 Q3	$2.71M	Buy	51,210 +41,210	+412%	+$2M	0.37%	58
2025 Q2	$421K	Sell	10,000 -156,074	-94%	-$5.94M	0.08%	58
2025 Q1	$6.29M	Buy	166,074 +93,558	+129%	+$5.84M	1.29%	26
2024 Q4	$5.58M	Buy	72,516 +5,471	+8%	+$396K	1.22%	29
2024 Q3	$3.86M	Sell	67,045 -251	-0.4%	-$13.6K	0.87%	37
2024 Q2	$2.78M	Sell	67,296 -123,260	-65%	-$5.83M	0.66%	37
2024 Q1	$11.6M	Sell	190,556 -93,285	-33%	-$4.18M	3.23%	10
2023 Q4	$6.32M	Buy	283,841 +9,313	+3%	+$168K	1.88%	18
2023 Q3	$7.04M	Buy	274,528 +42,784	+18%	+$809K	2.14%	15
2023 Q2	$4M	Buy	+231,744	New	+$3.55M	1.24%	28
2023 Q1	–	Sell	-6,561	Closed	-$234K	–	97
2022 Q4	$234K	Sell	6,561 -106	-2%	-$3.31K	0.07%	83
2022 Q3	$227K	Buy	+6,667	New	+$332K	0.08%	73

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Silverarc Capital Management's PRAX Position: Q1 2026 in Review

Silverarc Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 13% in Q1 2026, selling an estimated $3.38M and leaving 71,552 shares worth $23.1M. The position accounts for 2.35% of the portfolio, ranked #15.

Silverarc Capital Management first reported a position in PRAX in Q3 2022 and has held it in 14 quarters since. The position peaked at $24.3M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Silverarc Capital Management held 71,552 shares of Praxis Precision Medicines worth $23.1M as of Q1 2026.
Silverarc Capital Management sold 10,913 Praxis Precision Medicines shares in Q1 2026, an estimated $3.38M.
Praxis Precision Medicines made up 2.35% of Silverarc Capital Management's portfolio in Q1 2026, its #15 holding.
Silverarc Capital Management first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 14 quarters since.
Silverarc Capital Management's Praxis Precision Medicines position peaked at $24.3M in Q4 2025.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.